Open Menu

Meetings & Education

Research & Data

Practice & Patients

Career Development

News & Initiatives

Get Involved

Adjuvant sacituzumab govitecan (SG) plus nivolumab (N) in patients (pts) with muscle-invasive urothelial carcinoma (UC) at high-risk for recurrence.

download

Background:

Pts with muscle-invasive UC of the bladder or upper genitourinary tract who undergo radical cystectomy or nephroureterectomy are at high risk for cancer recurrence if residual pathologic advanced disease is identified at the time of surgery. Emerging data demonstrates that pts with minimal residual disease following curative-intent surgery, as detected by circulating tumor DNA (ctDNA), may be at a particularly high risk of UC recurrence. Adjuvant N has been approved post curative-intent surgery, with or without prior neoadjuvant chemotherapy (NAC), in pts with muscle-invasive UC at high risk of recurrence based on results of the CheckMate 274 study, which demonstrated a disease free survival (DFS) at 6 months of 74.9% with N versus 60.3% with placebo. SG is an antibody-drug conjugate with activity in UC. Evaluating intensification of adjuvant therapy in order to reduce the chance of metastasis development is of great interest.

Methods:

This is an IRB-approved, prospective, multi-center, single-arm phase 2 study of combination therapy with SG plus N. To be eligible, pts must have documented muscle-invasive UC, with variant and mixed histology allowed, except small cell. Pts must have undergone curative-intent surgery within 180 days prior to study therapy initiation and be radiographically free of metastasis. Pts who received prior NAC must have T2-T4 or node positive disease on surgical pathology, while those without NAC must have pathologic T3-T4 or node positive disease. Pts must also be ineligible or refuse platinum-based adjuvant chemotherapy. Additional selected eligibility criteria include creatinine clearance of at least 30 ml/min and adequate bone marrow function. If eligible for the study, pts will receive SG 7.5 mg/kg on day 1 and 8 combined with Nivolumab 360 mg on day 1 given every 21 days for 4 cycles, followed by single-agent Nivolumab 480 mg on day 1 given every 28 days for an additional 11 cycles. Use of growth factor support is allowed, as per institutional practice. Primary study endpoint is investigator-assessed DFS at 6 months. Secondary study endpoints include DFS, distant metastasis-free survival (MFS), overall survival (OS), incidence of grade 3 or higher adverse events, rate of ctDNA clearance in baseline ctDNA positive patients as well as exploratory biomarker analysis. The sample size calculation was based on a one-sided one sample test for exponential hazard rate when the probability of DFS at 6-months in the experimental group is 85% and in the historical control group is 75% in order to detect a hazard ratio of 0.565 with a power of 80% at a 0.05 significance level. Projected study accrual time is 24 months and per pt follow-up time is 36 months. Out of 23 anticipated pts, 3 have been enrolled to date since study activation in 11/2024. Clinical trial registry number: NCT06682728.

Disclaimer

Author Details

Nataliya Mar

University of California Irvine, Irvine, CA

Authors chevron_right

Associated Organizations chevron_right

Abstract Details

Meeting

2025 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Genitourinary Cancer—Kidney and Bladder

Track

Genitourinary Cancer—Kidney and Bladder

View MoreAbstract Disclosure
open_in_new

iframe iframe iframeBrand%3B24.0.0.0&uamb=0&uam=&uap=Linux%20x86_64&uapv=6.6.72&uaw=0&fledge=1&data=event%3Dgtag.config)

Download

Company Logo

Your Privacy

ASCO is committed to transparency regarding our websites and the ways we process data. When you visit our site, we may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences, your location, or your device and is mostly used to make the site work as you expect it to and to personalize your web experience with us.

Because we respect your right to privacy, you can choose not to allow some or all types of cookies. Click on the different category headings to find out more about the types of cookies used on our websites and change your default settings to match your preferences. Please read these carefully. Blocking some types of cookies may impact your experience on the site, including our ability to personalize the content you receive from us.

For a full explanation of the personal and non-personal information we collect on our site, including how we use that information and your rights regarding that information, please review our Privacy Policy. Use of our website is also subject to our Terms of Use.

Allow All

Essential Website Cookies

Always Active

These cookies are necessary for the website to function and are sometimes referred to as “strictly necessary” cookies. They make sure the website delivers you information and services in an optimal way.

They are often set in response to an action you take, such as changing your cookie preferences, setting your privacy preferences, logging in to our website, asking the site to remember you on subsequent pages, or filling in forms. These cookies do not identify you personally.

You can set your browser to block or alert you about all cookies, including essential website cookies, but some parts of the site will not work as a result.

Cookies Details‎

Performance and Functionality Cookies

These cookies enhance the performance and functionality of our websites and the services we provide. For example, these cookies can keep track of your visitor session in between visits, enable you to share content through social media, use embedded media players, and use comment features. They also help us balance website load and improve site speed and performance.

All information these cookies collect is aggregated and therefore anonymous. These cookies may be set by us or by third party providers whose services we have added to our websites. These cookies are non-essential, but without these cookies, certain functionality or enhanced features may become unavailable.

Cookies Details‎

Personalization and Analytics Cookies

These cookies collect information that is used to help us understand how our websites and content are used, help us customize our websites and application for you in order to enhance your experience, and help us improve the content that ASCO creates to better meet our members’ and visitors’ needs. Examples include cookies that show us which content might be most popular with our visitors, understand browsing history of our users, understand the effectiveness of our own advertising, and enable us to recommend content to individual users based on their profile and activities on the website.

These cookies may be set by us or by third party providers whose services we have added to our websites.

These cookies are non-essential to the functionality of the site and may contain information that enables us or our third party providers to identify you and build a profile of your interests. Without these cookies, you will not be able to have a customized or personalized experience within our website.

Cookies Details‎

Advertising Cookies and Social Media Cookies

Advertising (or Targeting) cookies are third party cookies that may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant ads on other sites.

Social Media Cookies are cookies set by a range of social media services that we have added to the site to enable you to share our content with your friends and networks. They are capable of tracking your activities across other sites and building a profile of your interests. This may impact the content and messages you see on other websites you visit.

These cookies and the data collected by the third parties may be combined with data from other users or data about your activity on other sites. While the data collected on our site is aggregate or non-personal, the data may be used by such third parties to link you on other platforms or otherwise identify you.

If you do not allow these cookies, you may experience less targeted advertising.

Cookies Details‎

Back Button

Search Icon

Filter Icon

Clear

checkbox labellabel

ApplyCancel

ConsentLeg.Interest

checkbox labellabel